Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
about
Long-acting beta2-agonists for chronic obstructive pulmonary diseaseLong-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysisTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseLong-acting beta2-agonists for poorly reversible chronic obstructive pulmonary diseaseIpratropium bromide versus long-acting beta-2 agonists for stable chronic obstructive pulmonary diseaseLong acting beta2 agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomised controlled trialsCOPD exacerbations. 4: PreventionCopd.Impact of bronchodilator therapy on exercise tolerance in COPD.Safety and efficacy of fluticasone propionate/salmeterol hydrofluoroalkane 134a metered-dose-inhaler compared with fluticasone propionate/salmeterol diskus in patients with chronic obstructive pulmonary diseaseChronic obstructive pulmonary disease, pollution, pulmonary vascular disease, transplantation, pleural disease, and lung cancer in AJRCCM 2001.The effect of cold temperature on increased exacerbation of chronic obstructive pulmonary disease: a nationwide studyEarly detection and management of COPD. What you can do to reduce the impact of this disabling disease.Chronic obstructive pulmonary disease . 7: Management of COPDLong-acting inhaled beta 2-agonists for stable COPD.Evaluating the cost-effectiveness of tiotropium versus salmeterol in the treatment of chronic obstructive pulmonary disease.Determinants of spirometry use and accuracy of COPD diagnosis in primary careHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDEffect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPDEarly onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis.FEV1 reversibility does not adequately predict effect of formoterol via Aerolizer in chronic obstructive pulmonary disease.Fluticasone propionate/salmeterol for the treatment of chronic-obstructive pulmonary disease.Effect of theophylline on exercise capacity in COPD patients treated with combination long-acting bronchodilator therapy: a pilot study.Pharmacological approaches to stable chronic obstructive pulmonary disease.New treatment strategies for COPD. Pairing the new with the tried and true.Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.Optimizing safety of COPD treatments: role of the nurse practitioner.The MCID of the transition dyspnea index is a total score of one unit.Improved outcomes in patients with chronic obstructive pulmonary disease treated with salmeterol compared with placebo/usual therapy: results of a meta-analysis.Pharmacotherapies for COPD.Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients.Long-acting beta-agonists reduce mortality of patients with severe and very severe chronic obstructive pulmonary disease: a propensity score matching study.Is combination therapy with inhaled anticholinergics and beta2-adrenoceptor agonists justified for chronic obstructive pulmonary disease?Quality indicators for the care of chronic obstructive pulmonary disease in vulnerable elders.Bronchodilators in COPD: impact of beta-agonists and anticholinergics on severe exacerbations and mortality.Pharmacological treatment of chronic obstructive pulmonary disease.Safety, tolerability and risk benefit analysis of tiotropium in COPD.Potential adverse effects of bronchodilators in the treatment of airways obstruction in older people: recommendations for prescribing.Optimizing bronchodilator therapy in emphysema.
P2860
Q24197467-1EBCD165-DE7B-478D-A05C-607650BEC079Q24197853-FE5CF3EF-0F8D-4674-9919-E58C7DE200E3Q24200476-B8393768-3C8D-4709-86C6-4A51B9D597D8Q24245141-C07681D2-2D4C-416A-9099-B4D2F876656CQ24245413-F0705DA9-44C6-422D-B20A-DD89043378D2Q24792685-BC56C9E7-74A0-46EF-A69F-BE0F2CC6E565Q30480789-D715CF3C-E047-4677-8651-FA3225A92D4EQ31016356-78D48631-BEAD-4B6E-984D-6581020245C5Q33831434-353FF14A-4363-4900-974A-C4E56C2668A5Q34501125-CF82215A-3249-467D-B4A5-C49061FEDCBFQ34550155-AADF8F97-F3FD-4B2D-8A4A-DB414D197A2CQ34647805-6CE8F295-7104-45A9-A600-B26193AE267DQ34705576-AA489F3D-A88C-482C-A548-A3E0E65AF066Q35075588-ADB82958-C9C5-4419-A1C7-96CB00329E99Q35201031-33767985-D22E-4C20-AEA8-3CDC00E7DD2AQ35205369-D6A0DD4A-5CAC-44F5-A8AE-167663D8E82CQ35527052-A33A7F25-FA3C-4CF5-BEE5-C662C22BC541Q35535912-5F6F8E38-22C6-453A-AD79-D1E5CC1CF412Q35536743-FDFC22F9-912C-4150-9771-F86B4C768522Q35537584-B4FC6C63-32B3-49E0-B813-EAC5AC4C9E3AQ35778149-22EC355C-F04E-4E80-A2A7-A2533BD84574Q35810452-7FDFCAB0-A7A9-47F3-9AC4-6F8BC42437B1Q35841604-53F39DF4-A808-4037-A42E-B67425D5598FQ35922109-085A6C8F-77DE-4099-B21F-2C4656EF2FF1Q35968315-C99D5AF4-82B0-431E-A1E8-746E5E0F2FFFQ36077028-3087E7F8-D490-4F93-97BD-CB60F00D8861Q36443665-E7DB3FCA-093E-4004-A17A-F7083D5121C7Q36642198-9599E7B7-1FF2-4ADF-9454-D84DAD831E20Q36669430-23B84C33-AD34-4CEC-B764-C68F986A46E0Q36695412-C40DF36F-CB14-4678-9823-6442956627B5Q36843717-B248B2A4-6B98-4FE7-8A5F-18022099E307Q36859446-CC66BD47-1F88-43AA-AC7F-FC6326A4FE86Q36908742-E825387D-A7FB-4927-8787-8A59133D8B84Q36911860-B17C1AC8-6617-419D-96AC-0B7A2414F798Q36957843-28F09124-0D0E-47DB-B9E7-9B92CC8A2BEAQ37017238-2EFEA476-E291-493F-B8FC-8544383FB996Q37017344-AB1BECB1-EA8C-4B10-8F4C-60BE50547BB1Q37115876-4DCA540A-3A62-4955-B7B6-6E289962BED0Q37151236-9304DA22-0560-4BE2-81BC-A3886A5CCDF7Q37153289-381B9C71-98B9-44DF-9AB1-9BC59346FDA7
P2860
Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@en
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@nl
type
label
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@en
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@nl
prefLabel
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@en
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@nl
P2093
P2860
P1476
Use of a long-acting inhaled b ...... obstructive pulmonary disease.
@en
P2093
Anderson W
Broughton J
Friedman M
Rennard SI
Wisniewski M
ZuWallack R
P2860
P304
P356
10.1164/AJRCCM.163.5.9903053
P407
P577
2001-04-01T00:00:00Z